AIDS Meds: Founded & Operated by People with HIVPOZ logo
Back to home » Top Stories » CROI 2008
CROI 2008 15th Conference on Retroviruses and Opportunistic Infections
Boston, MA
February 3-8, 2008

Sexual Reinfection With HCV Following Treatment

February 4, 2008

By Tim Horn

Reinfection with hepatitis C virus (HCV), after undergoing successful treatment for the liver infection, can occur following a subsequent sexual exposure to the virus, according new data involving eight gay and bisexual HIV-positive men reported today at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Evidence confirming that HCV can be spread sexually continues to mount, with the vast majority of reports involving men who have sex with men. There’s also no shortage of research confirming that individuals who successfully undergo a year of toxic antiviral treatment for HCV are not always in the clear—some patients see a relapse of their infection, whereas others can be reinfected with another strain of HCV via the same transmission route responsible for their first infection with the virus.

Rachel Jones, MD, of the Chelsea and Westminster NHS Foundation Trust in London, and her colleagues set out to determine whether infection relapse or reinfection was to blame for a resurgence of detectable HCV viral loads in a small group of HIV-positive gay and bisexual men, several months after being successfully treated for the hepatitis C.

The researchers first queried databases at both Chelsea and Westminster and Royal Free Hospitals to find individuals with detectable HCV viral loads following a sustained virologic response (SVR) to initial hepatitis C treatment. An SVR is typically defined as an undetectable HCV viral load for at least six months after spontaneously clearing the infection or following completion of standard treatment: pegylated interferon plus ribavirin.

Once the individuals were found, the genes from their HCV samples—collected during the first and second period of detectable virus—were compared. Sexually transmitted infection diagnoses during the HCV SVR—a potential marker of sexual behavior that may have facilitated a transmission of a second hepatitis C virus—were also recorded in the database.

Of the 211 HIV/HCV-coinfected individuals in the data, 16 had at least two episodes of HCV infection, with the second episode typically diagnosed following a routine liver function test. All were men who have sex with men. They had been infected with HIV for approximately four years and, on average, were 38 years old when they were diagnosed with the initial HCV infection. The average length of the SVR, between periods of detectable HCV, was 20 months.

Dr. Jones’s group was able to collect paired samples from eight of the individuals. Genetic analysis revealed two individuals with viruses that were similar enough to indicate late relapse. In the remaining six, there were enough differences between the paired viruses to indicate reinfection with different strains.

All but two individuals had at least one sexually transmitted infection during their SVR periods, syphilis being the most common.

In conclusion, Dr. Jones and her colleagues suggest that six of the men were likely reinfected with HCV after successfully completing treatment for an initial infection. These reinfections, the authors said, were likely related to ongoing high-risk sexual activity. In the other two patients, the strains were closely related, likely indicative of a late relapse of the infection—or possibly reinfection from a common source. 

NEW! Scroll down to comment on this story.

Name:

(2-50 characters)

Email:

(will not show)

City:

(optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

Dale, Tucson, 2008-02-19 19:18:58
great story "KUDOS" Like to see more on this subject as I Have duel exposure HIV?HCV(2)...... Thanks

comments 1 - 1 (of 1 total)    

Our general CROI conference coverage was sponsored by Abbott Laboratories, Boehringer Ingelheim and Gilead Sciences.

Additional funding, to support news and video coverage of women's issues at CROI, was provided by Tibotec Therapeutics.

More from CROI 2008

Starting and Switching Treatment
February 9, 2008

Durable Efficacy and Safety With Isentress Treatment

February 7, 2008

Durable Efficacy Seen in Studies of New NNRTI Intelence

Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosing

February 6, 2008

TDM-Guided PI Dose Increases of Limited Benefit

February 5, 2008

Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potency

Epzicom Comparable to Truvada as First-Line NRTI Choice

February 4, 2008

Norvir/Reyataz Comparable to Kaletra for First-Line Therapy



HIV/AIDS Complications and Treatment Side Effects
February 4, 2008

Abacavir, Didanosine Linked to Increased Heart Attack Risk

Sexual Reinfection With HCV Following Treatment



Experimental HIV Drugs
February 12, 2008

VIRxSYS Gene Therapy Makes Progress

February 9, 2008

Prezista Effective and Safe in Positive Kids

February 7, 2008

Nanotechnology May Yield Long-Lasting Meds

February 4, 2008

Vicriviroc Shows Well in Treatment-Experienced Patients



HIV Transmission and Prevention
February 9, 2008

Good Bacteria Reduces Vaginal HIV Levels

February 6, 2008

Male Circumcision Doesn't Reduce Women's HIV Risk



Expert Interviews
February 12, 2008

Women & HIV Treatment

World of Prevention: Vaccines and More

Condom-Free Sex? Controversial Swiss Declaration

February 11, 2008

New Hope for Treatment Experienced

February 8, 2008

HIV & Your Heart: Part I

HIV & Your Heart: Part II

Morris Jackson: Survivor and Treatment Activist

February 7, 2008

Prevention and Women: HIV-positive and HIV-negative

February 6, 2008

Refining HIV Treatment for New Med Takers

February 5, 2008

AIDS Survival: Progress Not Perfection


© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy